| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3.4 | 12.5 |
| Profit before tax | -31.0 | -16.7 |
| Net income | -31.0 | -16.7 |
| EPS (diluted, $ a share) | $-0.99 | $-0.59 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -72.9% |
|---|
10-Q filed with the SEC, NASDAQ: LENZ. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lenz Therapeutics, Inc.: key numbers
- Share price
- $3.50Close, Nov 17
- Market cap
- $110M
- Shares outstanding
- 31.42MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lenz Therapeutics, Inc.
All →Lenz Therapeutics 10% Owner Ra Capital Management L.P. Sells $9.13M of Stock
Ra Capital Management L.P., 10% Owner, sold 2,718,684 shares of Lenz Therapeutics, Inc. at $3.36 a share, worth $9.13M in total on Oct 29, 2026. Shares held after the trade: 57,559 (-65.1%).
- Value
- $9.13M
- Shares
- 2,718,684
- Average price
- $3.36
- Role
- 10% Owner
- Holding change
- -65.1%
- Trade date
- Oct 29, 2026
Lenz Therapeutics Financial Results
LENZ Therapeutics reported Q3 2026 financial results featuring a 50% sequential increase in VIZZ product sales. Alongside results, the company announced a strategic reorganization reducing headcount by 75% to focus on consumer marketing and a leadership transition where CEO Eef Schimmelpennink will be succeeded by CFO Dan Chevallard as Interim CEO on December 1, 2026.
- Term
- Q3 2026
“Our strong third-quarter results demonstrate continued progress in the commercialization of VIZZ, with product sales growth of 50%, increasing patient adoption and encouraging refill rates. We view these as promising indicators of our positive trajectory in this emerging market.”
Eef Schimmelpennink, President and Chief Executive Officer
“After nearly six years leading LENZ and more than 25 years in the biotechnology industry, I have decided to transition from my role as CEO effective December 1, 2026, to devote more time to other passions.”
Eef Schimmelpennink, President and Chief Executive Officer